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Idiopathic Hyposmia As a Preclinical Sign of
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Olfactory dysfunction is an early and common symptom in Parkinson’s disease (PD). In an effort to determine whether
otherwise unexplained (idiopathic) olfactory dysfunction is associated with an increased risk of developing PD, we
designed a prospective study in a cohort of 361 asymptomatic relatives (parents, siblings, or children) of PD patients. A
combination of olfactory detection, identification, and discrimination tasks was used to select groups of hyposmic (n 
40) and normosmic (n  38) individuals for a 2-year clinical follow-up evaluation and sequential single-photon emission
computed tomography (SPECT), using [123I]-CIT as a dopamine transporter ligand, to assess nigrostriatal dopaminer-
gic function at baseline and 2 years from baseline. A validated questionnaire, sensitive to the presence of parkinsonism,
was used in the follow-up of the remaining 283 relatives. Two years from baseline, 10% of the individuals with idio-
pathic hyposmia, who also had strongly reduced [123I]-CIT binding at baseline, had developed clinical PD as opposed
to none of the other relatives in the cohort. In the remaining nonparkinsonian hyposmic relatives, the average rate of
decline in dopamine transporter binding was significantly higher than in the normosmic relatives. These results indicate
that idiopathic olfactory dysfunction is associated with an increased risk of developing PD of at least 10%.
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Olfactory deficits in Parkinson’s disease (PD) were first
empirically documented in 1975.1 Over the ensuing
years, it has become clear that most patients with PD
have olfactory disturbances that are not restricted to a
single functional modality but include impairments of
odor detection, differentiation, and identification.2–6
At the earliest clinical stage of the disease, profound
deficits in each of these modalities have been demon-
strated.4,6 Olfactory deficits also have been found in
asymptomatic relatives of patients with either familial
or sporadic forms of PD.7,8 Recently, we reported a
subclinical degeneration of the nigrostriatal dopaminer-
gic system in some hyposmic relatives of PD patients.9
These findings suggest that olfactory dysfunction might
be a prodromal or preclinical sign of PD.
An important pathological characteristic of PD is the
degeneration of dopaminergic neurons located in the
substantia nigra, pars compacta, and their projections
to striatal regions. The extent of the degeneration of
the nigrostriatal dopaminergic system in PD can be vi-
sualized in vivo by means of positron emission tomog-
raphy (PET) or single-photon emission computed to-
mography (SPECT), using radioligands for the
dopamine transporter.10 Based on in vivo PET and
SPECT imaging of the dopaminergic system and post-
mortem cell counts of pigmented neurons in the sub-
stantia nigra, the onset of dopaminergic neuronal loss
seems to antedate the clinical diagnosis of PD by ap-
proximately 4 to 6 years.11–13 Over the period between
the presumed onset of dopaminergic neuronal loss and
the clinical diagnosis of PD, that is, the preclinical
phase of PD, as many as 58 to 64% of the dopami-
nergic neurons projecting to the putamen already have
been lost.14,15
PD-related pathological changes in the substantia
nigra are always accompanied by extensive extranigral
pathology.16 According to a novel and provocative
pathological staging system for PD by Braak and col-
leagues, the neuropathological process actually may
start in extranigral structures, including the olfactory
bulb and related portions of the anterior olfactory nu-
cleus.17 Assuming that PD-related pathology indeed
first occurs outside the nigra, the preclinical phase of
PD may be substantially longer than imaging data of
the nigrostriatal system suggest. Moreover, the early
pathological involvement of the anterior olfactory sys-
tem further emphasizes the potential value of hyposmia
as a preclinical sign of PD.
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Identifying subjects with an increased risk of devel-
oping PD may contribute to the development of neu-
roprotective treatment strategies, because a preclinical
diagnosis would not only allow neuroprotective agents
to be administered earlier in the disease process, but
also enable us to study proposed mechanisms of neu-
rodegeneration (such as oxidative stress) closer to the
onset of neuronal loss.18
The aim of this study was to determine whether oth-
erwise unexplained olfactory dysfunction is associated
with an increased risk of developing PD. To this end,
we set up a prospective study in a cohort of 361
asymptomatic relatives of PD patients. A combination
of olfactory tests was used to select groups of hyposmic
(n  40) and normosmic (n  38) individuals for a
2-year clinical follow-up evaluation and sequential
[123I]-CIT SPECT to assess nigrostriatal dopaminer-
gic function at baseline and 2 years from baseline. A
validated questionnaire, sensitive to the presence of
parkinsonism, was used in the follow-up of the remain-
ing 283 relatives.
Subjects and Methods
Study Population/Subjects
This study involved 361 first-degree relatives (285 children,
73 siblings, and 3 parents) of patients with sporadic PD.
Subjects were recruited partly from the general population
and partly from family members of patients at the outpatient
clinic for movement disorders of the VU University Medical
Center. As described previously,9 relatives were included
when they fulfilled the following criteria: (1) clinical diagno-
sis of PD in the affected relative obtained by a neurologist or
established retrospectively using information obtained from
the unaffected relatives; (2) absence of a history of other
(neuropsychiatric) disorders or conditions known to influ-
ence olfactory function; (3) no medication that might influ-
ence dopamine transporter binding and/or olfactory func-
tion; (4) absence of parkinsonism as defined by the United
Kingdom Parkinson’s Disease Society Brain Bank (UK-
PDSBB) criteria19; (5) Unified Parkinson’s Disease Rating
Scale (UPDRS) motor score less than 5; (6) Cambridge ex-
amination for mental disorders (CAMCOG) orientation and
memory section score greater than 26. All participants gave
written informed consent; the protocol of the study was ap-
proved by the Health Council of The Netherlands and the
local medical ethical committees of both the VU University
Medical Center and the Academic Medical Center. In a pre-
vious report, we have presented baseline data of the first 250
first-degree relatives who were included in this study.9
Study Design
At baseline, all 361 subjects were submitted to a combina-
tion of olfactory processing tasks (Fig 1). Considering the
superior sensitivity and specificity of a combination of olfac-
tory processing tasks over any individual test,6 the average
Z-score over the three olfactory tests was chosen as a measure
of olfactory function. Participants were selected for SPECT
scanning from five consecutive groups of 70 to 80 partici-
pants to limit the interval between olfactory testing and base-
line SPECT scanning. To reduce the effect of age- and sex-
related differences in olfactory performance,20 we created a
rank order based on average Z-scores for men and women
separately in the three groups of subjects aged 50 to 59 years
and in the two groups of individuals aged 60 to 75 years. In
each group, those individuals with the 10% lowest average
Z-scores (with the additional requirement that the perfor-
mance on each of the olfactory tasks had to be below group
average) were considered hyposmic. In this way, 40 hypos-
mic relatives (29 children, 11 siblings) were identified. Sim-
ilarly, 38 relatives (31 children, 2 siblings) with the highest
average Z-scores (and all olfactory scores above group mean)
were selected. The groups selected for SPECT scanning did
not differ in demographics (Table 1).
Two years from baseline, 72 of the 78 individuals that
were scanned at baseline were available for a follow-up
screening with repeated SPECT scanning, neuropsychologi-
cal testing, and neurological evaluation (see Fig 1). Of the
283 relatives not selected for baseline SPECT scanning, 275
completed a questionnaire sensitive to the presence of par-
kinsonism as part of the 2-year follow-up evaluation (see Fig
1). Relatives with possible parkinsonism according to the
questionnaire were invited to the outpatient clinic for move-
ment disorders of the VU University Medical Center for
clinical evaluation.
Olfactory Processing Tasks
Olfactory function was assessed, as described previously, by
means of a combination of an odor detection, an odor dis-
crimination task, and an odor identification task.9
Clinical and Neuropsychological Evaluation
Two years from baseline, clinical evaluation of all individuals
selected for [123I]-CIT SPECT scanning was conducted by
a movement disorders specialist and included a screening
neurological examination and a specific assessment to detect
the presence of parkinsonism as defined by the UK-PDSBB
criteria.1 Motor function was rated by means of the motor
section of the UPDRS. A UPDRS motor score of five or
more was considered as a sign of motor dysfunction, not
necessarily as part of a parkinsonian syndrome. Individuals
who had developed clinical PD before the 2-year follow-up
evaluation and were already using medication were tested
off-medication, at least 12 hours after their evening dose.
In addition to the neurological evaluation, the CAMCOG
also was repeated 2 years from baseline. A CAMCOG score
under 27 was considered indicative of cognitive dysfunction
possibly as part of a developing dementing illness.
Individuals with possible parkinsonism according to the
questionnaire were submitted to a structured clinical workup,
comprising a standard history taking and a neurological ex-
amination including the UPDRS motor score. A blinded
movement disorders specialist, not involved in the baseline
screening, performed the structured clinical workup.
Single-Photon Emission Computed Tomography
Scanning
SPECT scanning and analysis of bilateral striatal, bilateral
putamen, and bilateral caudate [123I]-CIT binding for each
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baseline and follow-up scan was performed using a previ-
ously described method.9 Four baseline SPECT scans, in one
hyposmic relative and three normosmic relatives, could not
be analyzed quantitatively because of technical problems. All
SPECT scans were analyzed by the same investigator,
blinded to olfactory performance.
Questionnaire
A Dutch translation of a screening questionnaire for PD, de-
signed by Tanner and colleagues21 and validated by Duarte
and colleagues22 was administered 2 years from baseline.
This mail questionnaire comprises nine symptom questions.
Fig 1. Flowchart illustrating the overall design of the study. *Two lost to follow-up, one of whom died. **Eight lost to follow-up,
five of whom died. ***Three normosmic relatives and one hyposmic relative switched to the questionnaire group. ****One relative
did not have SPECT because of selective serotonin reuptake inhibitor use. PD  Parkinson’s disease; SPECT  single-photon
emission computed tomography.
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With a cutoff score of three or more positive responses, sen-
sitivity and specificity to detect parkinsonism are 95% and
89%, respectively. An extra question was added to establish
whether a physician had made a diagnosis of PD over the
course of the follow-up period. Three or more positive re-
sponses to the screening questionnaire, as well as a positive
response to the additional question, were considered indica-
tive of possible parkinsonism.
Data Analysis
For both baseline and follow-up SPECT scans, group means
of each binding parameter were calculated and compared by
means of Student’s unpaired t test. In addition, age-adjusted
means of each SPECT parameter, including its 95% confi-
dence interval, were determined in the group of normosmic
relatives. Individual values of hyposmic relatives were consid-
ered abnormal if they fell outside the 95% confidence inter-
val of the age-adjusted means of the group of normosmic
individuals.
Changes in [123I]-CIT binding ratios over the 2-year
follow-up period were analyzed by calculating the rate of
change in [123I]-CIT binding expressed as a percentage of
baseline [123I]-CIT binding for each participant and each
SPECT parameter using the following formula:
(follow-up SPECT baseline SPECT)
baseline SPECT
 100%
Because the baseline scans of three normosmic and a sin-
gle hyposmic relative could not be analyzed quantitatively,
changes in [123I]-CIT binding over time could be deter-
mined for 30 normosmic relatives and 38 hyposmic relatives.
Linear regression analysis was used to compare changes in
[123I]-CIT binding ratios over time between the groups.
The 2-year follow-up data were used as the dependent vari-
able and group as an independent variable. By adding the
baseline value as an independent variable, changes in [123I]-
CIT binding ratios are corrected for the baseline value. Be-
cause age and sex did not differ between the groups (using
univariate analysis of variance and a 2 test, respectively),
these factors were not used as independent variables.
Results
Olfactory Processing Tasks
The average scores on the different olfactory processing
tasks are listed in Table 2. Olfactory task performance
in the group of selected hyposmic relatives was compa-
rable to that of patients in the early clinical stages of
PD.
Neuropsychological Testing
A single hyposmic relative had a CAMCOG score of
24, 2 years from baseline. An additional neurological
and neuropsychological evaluation combined with a
magnetic resonance imaging scan of the brain led to a
diagnosis of mild cognitive impairment most likely
with a vascular cause.
Clinical Evaluation
Two years from baseline, four relatives of the original
group of 40 hyposmic relatives had developed clinical
PD as defined by the UK-PDSBB criteria. First clinical
symptoms appeared 9 to 19 months after baseline test-
ing. Two years from baseline, off-medication UPDRS
motor scores were, respectively, 10, 15, 15, and 18.
Two relatives were taking a dopamine-agonist and a
combination of a dopamine-agonist with L-dopa, re-
spectively, and had a good clinical response. The other
two relatives were not taking antiparkinsonian medica-
tion. None of the other hyposmic relatives, nor any of
the normosmic relatives available for clinical follow-up,
fulfilled the criteria for a parkinsonian syndrome ac-
cording to the UK-PDSBB criteria. Three normosmic
relatives and one hyposmic relative had UPDRS motor
scores ranging from 6 to 8. However, because none of
these relatives had signs of a progressive disorder, they
did not fulfill UK-PDSBB criteria for PD.
In the questionnaire group, 10 subjects had three or
four (of nine) positive responses to the screening ques-
tionnaire. Clinical evaluation did not show a parkinso-
nian syndrome in these subjects; all UPDRS motor
scores were under 5. No subject had a positive response
to the additional question.
[123I]-CIT Single-Photon Emission Computed
Tomography Imaging
Mean SPECT binding ratios at baseline and 2 years
from baseline for the hyposmic and normosmic groups
are listed in Table 3. At baseline, a slight, but not sta-
tistically significant difference was found between the
groups. Two years from baseline, mean bilateral striatal
and putamen binding ratios were significantly lower in
the group of hyposmic relatives compared with the
group of normosmic relatives.
Despite the absence of significant group differences
in [123I]-CIT binding at baseline, 7 of the 39 hypos-
mic relatives showed one or more reduced [123I]-CIT
binding ratios outside the 95% confidence interval of
the age-adjusted means of the normosmic relatives (left
and right striatal [123I]-CIT binding ratios are illus-
trated in Fig 2). In three hyposmic relatives, all of six
binding ratios calculated were strongly reduced. Two
hyposmic relatives had two abnormal values, that is,
right striatal combined with either right putamen or
right caudate [123I]-CIT binding. Last, two hyposmic
relatives each had a single binding ratio deviating mar-
Table 1. Demographic Data for Participants
Demographic
All
Subjects
(n  361)
Normosmic
Relatives
(n  38)
Hyposmic
Relatives
(n  40)
Sex (male/female) 157/204 17/21 19/21
Age (mean  SD) 58.7 6.6 58.5 6.6 59.2  5.8
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ginally from normosmic control values, that is, reduced
right putamen and right striatum [123I]-CIT binding
ratio, respectively. A single normosmic relative had a
marginally reduced right striatal [123I]-CIT binding
ratio. Interestingly, the four hyposmic relatives with
the most strongly reduced baseline [123I]-CIT bind-
ing (the three relatives with all binding ratios reduced
and the relative with reduced right striatal and right
putamen [123I]-CIT binding ratios) developed clinical
PD 9 to 19 months from baseline scanning (see
above).
Two years from baseline, five hyposmic relatives had
three or more reduced [123I]-CIT binding ratios (left
and right striatal [123I]-CIT binding ratios are illus-
trated in Fig 3). These included the four relatives who
developed clinical PD. The fifth relative, who had an
isolated reduced right putamen binding ratio at base-
line, now had reduced left striatal and bilateral puta-
men [123I]-CIT binding ratios. All other relatives
with initially reduced [123I]-CIT binding ratio(s) had
normal scans 2 years from baseline. In a single normos-
mic relative (who had normal [123I]-CIT binding ra-
tios at baseline) right striatal and right putamen bind-
ing ratios were just outside the 95% confidence
interval of normosmic values.
The mean rates of change in [123I]-CIT binding
ratios over the 2-year follow-up period are listed in Ta-
ble 4. With the exception of left caudate [123I]-CIT
binding, the average rate of decline in all other [123I]-
CIT binding ratios was significantly higher in the
group of hyposmic relatives than in the group of nor-
mosmic relatives, even when the four hyposmic rela-
tives who developed clinical PD were excluded from
the analysis. In the group of hyposmic relatives, the
rate of decline in caudate [123I]-CIT uptake was
lower than the rate of decline in putamen uptake.
Figure 4 illustrates the individual values for the rates
of change in left and right striatal [123I]-CIT binding,
expressed as percentage change from baseline in
[123I]-CIT binding ratios. A particularly rapid loss of
binding occurred in five, as of yet nonparkinsonian hy-
posmic relatives, three of whom had high (deviating
from the normosmic control values) baseline striatal
binding values. Among these relatives with rapid loss of
binding was the only nonparkinsonian hyposmic rela-
tive with reduced [123I]-CIT binding ratios 2 years
from baseline. In contrast, the single normosmic rela-
tive with two slightly decreased absolute binding ratios
2 years from baseline did not have an increased rate of
decline in striatal binding over the 2-year period.
Discussion
In this prospective study in a cohort of first-degree rel-
atives of PD patients, only those individuals with an
otherwise unexplained hyposmia as well as strongly re-
duced [123I]-CIT binding ratios at baseline, indicative
of a subclinical degeneration of the dopaminergic sys-
tem, went on to develop clinical PD within a
follow-up period of 2 years. Two-year follow-up
SPECT scanning showed an additional hyposmic rela-
Table 2. Scores on Olfactory Processing tasks (mean  SD), Measured at Baseline
All Subjects
(n  361)
Normosmic Relatives
(n  38)
Hyposmic Relatives
(n  40)
Early PD
(group size)
Odor detection 13.3 2.1 14.8 1.3 10.8 1.9 11.0 2.6 (n 24)
Odor discrimination 20.9 4.5 25.7 2.0 15.5 3.6 17.4  4.9 (n 24)
Odor identification 9.7 1.7 10.9  0.9 7.3 2.1 7.5 3.1 (n 14)
The results of olfactory testing using the same tasks in groups of early stage PD patients are listed for comparison.
SD  standard deviation; SPECT  single-photon emission computed tomography; PD  Parkinson’s disease.
Table 3. Specific to Nonspecific [123I]-CIT Binding Ratios (mean  SD) at Baseline and at 2 Years
Location
Baseline Two-Year Follow-up
Normosmic Relatives
(N  35)
Hyposmic Relatives
(N  39)
Normosmic Relatives
(N  32)
Hyposmic Relatives
(N  39)
Left striatum 5.38 0.7 5.26 1.5 5.44 0.9 4.86 1.1a
Right striatum 5.25 0.7 5.13 1.4 5.28 0.9 4.74  1.1a
Left putamen 4.33 0.6 4.16 1.2 4.31 0.8 3.69  0.9a
Right putamen 4.05 0.6 3.85 1.1 4.04 0.8 3.55  1.0a
Left caudatus 6.35 0.8 6.33 1.9 6.39 1.1 5.92  1.3
Right caudatus 6.41 0.8 6.41 1.7 6.46 1.2 5.91 1.3
aSignificantly different from normosmic group (p  0.05).
SD  standard deviation; PD  Parkinson’s disease.
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Fig 2. Scatterplots of left (A) and right (B) striatal [123I]-CIT binding ratios at baseline. Normosmic relatives (open circles; n 
35) Hyposmic relatives (filled circles; n  35); hyposmic relatives who developed clinical parkinsonism (fill triangles; n  4); the
age-adjusted means and the 95% confidence interval of [123I]-CIT binding values in the group of normosmic relatives (solid
lines).
Fig 3. Scatterplots of left (A) and right (B) striatal [123I]-CIT binding ratios 2 years from baseline. Normosmic relatives (open
circles; n  32); hyposmic relatives (filled circles; n  35); hyposmic relatives who developed clinical parkinsonism (filled trian-
gles; n  4); the age-adjusted means and the 95% confidence interval of [123I]-CIT binding values in the group of normosmic
relatives (solid lines).
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tive with strongly reduced [123I]-CIT binding ratios.
Moreover, in the group of hyposmic relatives, the av-
erage rate of decline in dopamine transporter binding
was significantly higher than in the group of normos-
mic relatives.
In the age group studied (50–75 years), the preva-
lence of clinical PD is approximately 1%, whereas the
prevalence of incidental Lewy Body disease (ILBD),
which is supposed to represent the preclinical stage of
PD, is at least 4%.19 In our population of 361 relatives
of PD patients, there should be at least 14 to 15 indi-
viduals with ILBD. This number actually could be
even higher, because relatives of PD patients have a
three to four times higher prevalence of clinical
PD.23,24 So far, four relatives in our cohort developed
clinical PD over a period of 2 years. Another five
asymptomatic hyposmic relatives, one of whom also
had abnormally reduced [123I]-CIT binding 2 years
from baseline, had a particularly rapid decrease in
[123I]-CIT binding over the 2-year follow-up period
(far exceeding the expected age related decline25), pos-
sibly indicating subclinical disease.
Motor signs (bradykinesia, gait disorders, rigidity,
and tremor) without underlying neurological disease
are commonly found during clinical examinations of
elderly subjects and their prevalence increases strongly
with age.26,27 The presence of a slight motor dysfunc-
tion in three normosmic and one hyposmic relatives (as
evidenced by a UPDRS motor score between 6 and 8)
therefore is not necessarily indicative of a developing
parkinsonian syndrome. More extensive follow-up will
be conducted to resolve this issue.
The average annual rate of decline in striatal [123I]-
CIT binding was increased in both the small group of
hyposmic relatives who later developed clinical PD as
well as in the group of hyposmic relatives that re-
mained asymptomatic. The average change in striatal
[123I]-CIT binding in the four hyposmic relatives
who developed PD during the follow-up period of 2
years was 6.3%, which is less than the 6 to 13% an-
nual reduction found in previous studies.11,12,28,29
However, this difference may be related to a single out-
lier (Fig 4A, B) in this small group. Among the hypos-
mic relatives that remained asymptomatic, the average
annual decline in [123I]-CIT binding was 3%. Five
asymptomatic but hyposmic relatives had a particularly
high annual loss of striatal binding of 15 to 23% (30–
45% over 2 years), possibly indicative of an early ac-
celerated degeneration of the nigrostriatal dopaminer-
gic system in the preclinical phase of PD. It could, of
course, be argued that this high annual rate of decline
in [123I] -CIT binding might be explained by inter-
individual variability. Given an age-related annual re-
duction in striatal [123I]-CIT uptake in healthy sub-
jects of only 0.8%,25 this is not very likely.
Furthermore, none of the normosmic relatives in our
study had a comparably high rate of decline in striatal
binding (see Fig 4).
In designing this study, it appeared to be difficult to
define hyposmia in an absolute way, given the substan-
tial interindividual differences in olfactory function as
well as important age- and sex-related effects. Never-
theless, using arbitrary cutoff values based on average
Z-scores, we were able to demonstrate that (otherwise
unexplained) diminished olfactory performance is asso-
ciated with an increased risk of developing PD. Along
the course of our longitudinal study, with more indi-
viduals developing clinical PD, we may be able to de-
rive more exact cutoff values for the olfactory tasks
used.
Based on the number of hyposmic relatives of PD
patients (4 of 40) who developed clinical PD so far,
idiopathic olfactory dysfunction seems to confer a risk
of 10% of developing PD. The increased rate of de-
cline in [123I]-CIT binding, suggestive of a subclini-
cal degeneration of the nigrostriatal system, in another
12% of hyposmic relatives, indicates that the risk of
developing PD in the presence of idiopathic hyposmia
may be as high as 22%. A more extensive follow-up of
the cohort of relatives of PD patients is required to
determine whether these subjects with an increased rate
of loss of [123I]-CIT binding indeed will go on to
Table 4. Percentage Change from Baseline (mean  SD) of [123I]-CIT Binding Ratios over the 2 Year Follow-up Period
Location
Normosmic Relatives,
Total (N  30)
Hyposmic Relatives
Total
(N  38)
No Parkinsonism
(N  34)
Parkinsonism
(N  4)
Left striatum 2.46 17.3 5.61 18.5a 5.59 17.8a 5.75 26.9
Right striatum 2.61 17.0 6.27 17.7a 6.19 16.5a 6.94 29.0
Left putamen 0.60 19.0 10.04 15.2a 9.85 15.3a 11.64 16.4
Right putamen 1.99 18.0 7.03 19.5a 6.46 18.1a 11.91 32.4
Left caudate 2.14 17.5 3.81 20.3 3.76 19.7 4.24 29.2
Right caudate 2.84 18.8 5.94 19.4a 6.57 18.8a 0.59 26.5
Linear regression analysis using absolute [123I]-CIT binding ratios (Table 3) was used to analyze group differences.
aSignificantly different from normosmic group (p  0.05)
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develop clinical signs of PD. Note also that the risk of
PD associated with hyposmia strongly depends on the
operational definition of hyposmia used and therefore
may further increase with more exact cutoff values for
the olfactory tests used.
Predating the diagnosis of PD and identifying sub-
jects at risk is an important and young research topic.18
With the development of neuroprotective treatment
strategies,30–32 an earlier diagnosis will allow a more
timely application of such treatments and also increase
the time window available for neuroprotection. On the
basis of these results, the olfactory approach to the
early diagnosis of PD appears to be particularly prom-
ising. Other potentially useful methods to detect pre-
clinical PD include ultrasound imaging of the substan-
tia nigra aimed at demonstrating increased echogenicity
of the substantia nigra33 and the use of a battery of
clinical tests designed to detect subtle (non)motor
manifestations of PD.34,35 However, the predictive
value of these other methods for the subsequent devel-
opment of clinical PD remains to be determined.
Recent neuropathological observations show exten-
sive extranigral neuropathological changes in idiopathic
PD, including the olfactory bulb and related portions
of the anterior olfactory nucleus.17,36,37 In the novel
and challenging pathological staging system for PD put
forward by Braak and colleagues, Lewy body pathology
in these anterior olfactory structures actually precedes
involvement of the substantia nigra. The authors hy-
pothesize that the anterior olfactory system may be one
of the induction sites of the neuropathological process
in PD. The presence of high numbers of dopaminergic
neurons in the olfactory bulb might lead to the as-
sumption that olfactory dysfunction in PD might well
be related to a loss of dopaminergic neurons. Quite to
the contrary, a recent study in postmortem brain tissue
showed a doubling of the number of dopaminergic
neurons in the olfactory bulb of PD patients relative to
age-matched controls.38 Although the precise patho-
physiology of the olfactory deficits in PD remains to be
elucidated, the early pathological involvement of the
olfactory system in PD is quite in line with our obser-
vation that hyposmia may precede clinical motor signs
in PD.
In conclusion, our results indicate that olfactory dys-
function in first-degree relatives of PD patients is asso-
ciated with an increased risk of developing clinical PD
of at least 10%. In contrast, in individuals with intact
olfactory function the risk appears to be lower than in
the general population. Considering the increased rate
of decline in dopamine transporter binding in the
group of hyposmic relatives, extending the follow-up
period of this cohort of relatives may reveal that the
risk of PD associated with idiopathic hyposmia is ac-
tually considerably higher.
This study was supported by a grant from ZorgOnderzoek Neder-
land (28-3062-1, H.W.B.).
We thank International Flavors and Fragrances for providing the
odorants.
Fig 4. Scatterplots of the rate of change in left (A) and right
(B) striatal [123I]-CIT binding ratios over the 2-year
follow-up period. Normosmic relatives (open circles; n  30);
hyposmic relatives (filled circles; n  34); hyposmic relatives
who developed clinical parkinsonism (filled triangles; n  4);
mean change in [123I]-CIT binding values (solid lines).
180 Annals of Neurology Vol 56 No 2 August 2004
References
1. Ansari KA, Johnson A. Olfactory function in patients with Par-
kinson’s disease. J Chronic Dis 1975;28:493–497.
2. Ward CD, Hess WA, Calne DB. Olfactory impairment in Par-
kinson’s disease. Neurology 1983;33:943–946.
3. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in
Parkinson’s disease. J Neurol Neurosurg Psychiatry 1987;50:
88–89.
4. Doty RL, Stern MB, Pfeiffer C. Bilateral olfactory dysfunction
in early stage treated and untreated idiopathic Parkinson’s dis-
ease. J Neurol Neurosurg Psychiatry 1992;55:138–142.
5. Hawkes CH, Shephard BC, Daniel SE. Olfaction disorders in
Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:
436–446.
6. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction
in de novo and treated Parkinson’s disease: possible implica-
tions for early diagnosis. Mov Disord 2001;16:41–46.
7. Montgomery EB Jr, Baker KB, Lyons K, et al. Abnormal per-
formance on the PD test battery by asymptomatic first-degree
relatives. Neurology 1999;52:757–762.
8. Markopoulou K, Larsen KW, Wszolek EK, et al. Olfactory dys-
function in familial parkinsonism. Neurology 1997;49:
1262–1267.
9. Berendse HW, Booij J, Francot CM, et al. Subclinical dopami-
nergic dysfunction in asymptomatic Parkinson’s disease pa-
tients’ relatives with a decreased sense of smell. Ann Neurol
2001;50:34–41.
10. Booij J, Tissingh G, Winogrodzka A, et al. Imaging of the do-
paminergic neurotransmission system using single-photon emis-
sion tomography and positron emission tomography in patients
with parkinsonism. Eur J Nucl Med 1999;26:171–182.
11. Marek K, Innis R, van Dyck C, et al. [123I]-CIT SPECT
imaging assessment of the rate of Parkinson’s disease progres-
sion. Neurology 2001;57:2089–2094.
12. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of
progression and estimating the preclinical period of Parkinson’s
disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry
1998;64:314–319.
13. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substan-
tia nigra regional selectivity. Brain 1991;114:2283–2301.
14. Tissingh G, Bergmans P, Booij J, et al. Drug-naive patients
with Parkinson’s disease in Hoehn and Yahr stages I and II
show a bilateral decrease in striatal dopamine transporters as
revealed by [123I]-CIT SPECT. J Neurol 1998;245:14–20.
15. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-
fluoropropyl-2-carbomethoxy-3-(4-iodophenyl)tropane
SPECT in healthy controls and early-stage, drug-naive Parkin-
son’s disease. J Nucl Med 1998;39:1143–1148.
16. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neu-
rol 2000;247(suppl 2):II3–II10.
17. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathol-
ogy related to sporadic Parkinson’s disease. Neurobiol Aging
2003;24:197–211.
18. DeKosky ST, Marek K. Looking backward to move forward:
early detection of neurodegenerative disorders. Science 2003;
302:830–834.
19. Gibb WR, Lees AJ. The relevance of the Lewy body to the
pathogenesis of idiopathic Parkinson’s disease. J Neurol Neuro-
surg Psychiatry 1988;51:745–752.
20. Doty RL. Studies of human olfaction from the University of
Pennsylvania Smell and Taste Center. Chem Senses 1997;22:
565–586.
21. Tanner CM, Gilley DW, Goetz CG. A brief screening ques-
tionnaire for parkinsonism. Ann Neurol 1990;28:267–268.
22. Duarte J, Claveria LE, Pedro-Cuesta J, et al. Screening Parkin-
son’s disease: a validated questionnaire of high specificity and
sensitivity. Mov Disord 1995;10:643–649.
23. Payami H, Larsen K, Bernard S, et al. Increased risk of Parkin-
son’s disease in parents and siblings of patients. Ann Neurol
1994;36:659–661.
24. Uitti RJ, Shinotoh H, Hayward M, et al. “Familial Parkinson’s
disease”—a case-control study of families. Can J Neurol Sci
1997;24:127–132.
25. Dyck van CH, Seibyl JP, Malison RT, et al. Age-related decline
in striatal dopamine transporter binding with iodine-123--
CIT SPECT. J Nucl Med 1995;36:1175–1181.
26. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of par-
kinsonian signs and associated mortality in a community pop-
ulation of older people. N Engl J Med 1996;334:71–76.
27. Wilson RS, Schneider JA, Beckett LA, et al. Progression of gait
disorder and rigidity and risk of death in older persons. Neu-
rology 2002;58:1815–1819.
28. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of
dopaminergic degeneration in Parkinson’s disease and atypical
parkinsonism: a longitudinal -CIT SPECT study. Mov Disord
2002;17:45–53.
29. Winogrodzka A, Bergmans P, Booij J, et al. [123I] -CIT
SPECT is a useful method for monitoring dopaminergic degen-
eration in early stage Parkinson’s disease. J Neurol Neurosurg
Psychiatry 2003;74:294–298.
30. Parkinson Study Group. Pramipexole vs levodopa as initial
treatment for Parkinson disease: a randomized controlled trial.
JAMA 2000;284:1931–1938.
31. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of
Parkinson’s disease with ropinirole versus levodopa: the REAL-
PET study. Ann Neurol 2003;54:93–101.
32. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme
Q10 in early Parkinson disease: evidence of slowing of the func-
tional decline. Arch Neurol 2002;59:1541-1550.
33. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the
substantia nigra—association with increased iron content and
marker for susceptibility to nigrostriatal injury. Arch Neurol
2002;59:999–1005.
34. Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson’s
disease. Adv Neurol 1999;80:327–333.
35. Tetrud JW. Preclinical Parkinson’s disease: detection of motor
and nonmotor manifestations. Neurology 1991;41:69–71.
36. Del Tredici K, Rub U, de Vos RA, et al. Where does parkinson
disease pathology begin in the brain? J Neuropathol Exp Neu-
rol 2002;61:413–426.
37. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nu-
cleus in Parkinson’s disease. Mov Disord 1995;10:283–287.
38. Huisman E, Uylings H, Hoogland P. A 100% increase of do-
paminergic cells in the olfactory bulb may explain hyposmia in
Parkinson’s Disease. Mov Disord 2004;19:687–692.
Ponsen et al: Hyposmia Increases Risk of PD 181
